Evidence map›Paper›PMID 34480749›Full record

ReviewDrugs2021

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.

Barbara Stella, Francesca Baratta, Carlo Della Pepa, Silvia Arpicco, Daniela Gastaldi, Franco Dosio

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Barbara StellaDepartment of Drug Science and Technology, University of Turin, v. P. Giuria, 9, 10125, Turin, Italy.
Francesca BarattaDepartment of Drug Science and Technology, University of Turin, v. P. Giuria, 9, 10125, Turin, Italy.
Carlo Della PepaDepartment of Drug Science and Technology, University of Turin, v. P. Giuria, 9, 10125, Turin, Italy.
Silvia ArpiccoDepartment of Drug Science and Technology, University of Turin, v. P. Giuria, 9, 10125, Turin, Italy.
Daniela GastaldiDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Franco DosioDepartment of Drug Science and Technology, University of Turin, v. P. Giuria, 9, 10125, Turin, Italy. franco.dosio@unito.it.ORCID http://orcid.org/0000-0003-1128-9922
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of Cannabis sativa L. research for medical purposes has been rapidly advancing in recent decades and a growing body of evidence suggests that phytocannabinoids are beneficial for a range of conditions. At the same time impressing development has been observed for formulations and delivery systems expanding the potential use of cannabinoids as an effective medical therapy. The objective of this review is to present the most recent results from pharmaceutical companies and research groups investigating methods to improve cannabinoid bioavailability and to clearly establish its therapeutic efficacy, dose ranges, safety and also improve the patient compliance. Particular focus is the application of cannabinoids in pain treatment, describing the principal cannabinoids employed, the most promising delivery systems for each administration routes and updating the clinical evaluations. To offer the reader a wider view, this review discusses the formulation starting from galenic preparation up to nanotechnology approaches, showing advantages, limits, requirements needed. Furthermore, the most recent clinical data and meta-analysis for cannabinoids used in different pain management are summarized, evaluating their real effectiveness, in order also to spare opioids and improve patients' quality of life. Promising evidence for pain treatments and for other important pathologies are also reviewed as likely future directions for cannabinoids formulations.

Indexed as

CannabisChronic PainClinical Trials as TopicDose-Response Relationship, DrugDrug Administration RoutesDrug CompoundingDrug Delivery SystemsHumansMedical MarijuanaNanotechnologyPain ManagementPlant ExtractsReceptors, CannabinoidMedical MarijuanaPlant ExtractsReceptors, Cannabinoid

Identifiers

PMID34480749
PMCPMC8417625
OpenAlexW3197127499

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.